More Chemotherapy Does Not Obviate the Need for Radiation Therapy (RT): Treatment for Early-Stage Favorable Hodgkin Lymphoma According to the HD10 Trial Compared With Chemotherapy Alone

被引：1
|
作者：
Pinnix, C. C. [1 ]
Abou Yehia, Z. [1 ]
Smith, G. L. [1 ]
Milgrom, S. A. [1 ]
Ho, J. C. [1 ]
Reddy, J. [1 ]
Gunther, J. R. [2 ]
Akhtari, M. [1 ]
Osborne, E. M. [1 ]
Medeiros, L. J. [1 ]
Fanale, M. [1 ]
Dabaja, B. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Div Radiat Oncol, Houston, TX 77030 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 96卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2016.06.1858
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3203
引用
收藏
页码：E489 / E490
页数：2
相关论文
共 50 条
  • [41] Positron Emission Tomography- (PET) guided Treatment in early-Stage Hodgkin Lymphoma with favorable Risk Factors: Final Results of the international randomized Phase III HD16 Trial conducted by the German Hodgkin Study Group
    Nieder, Carsten
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (04) : 414 - 415
  • [42] Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix (Reprinted from vol 18, pg 1606, 2000)
    Peters, William
    Liu, P. Y.
    Barrett, Rolland
    Stock, Richard
    Monk, Bradley
    Berek, Jonathan
    Souhami, Luis
    Grigsby, Perry
    Gordon, William
    Alberts, David
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (29) : 4605 - 4612
  • [43] Fifteen year experience of A(E)BVD chemotherapy plus low dose involved field radiation therapy for early clinical stage Hodgkin's lymphoma (HL). Does radiation dose affect patients' outcome?
    Vassilakopoulos, TP
    Angelopoulou, MK
    Siakantaris, MP
    Kyrtsonis, MC
    Kontopidou, FN
    Dimopoulou, MN
    Kokoris, SI
    Dimitriadou, E
    Tsaftaridis, P
    Variamis, E
    Zambatis, H
    Michalopoulos, E
    Boussiotis, VA
    Panagiotidis, P
    Papavassileiou, K
    Pangalis, GA
    BLOOD, 2003, 102 (11) : 405A - 405A
  • [44] Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
    Rosenbrock, Johannes
    Kaul, Helen
    Oertel, Michael
    Celik, Eren
    Linde, Philipp
    Fan, Jiaqi
    Eichenauer, Dennis A.
    Broeckelmann, Paul J.
    von Tresckow, Bastian
    Kobe, Carsten
    Dietlein, Markus
    Fuchs, Michael
    Borchmann, Peter
    Eich, Hans Theodor
    Baues, Christian
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (05): : 1344 - 1352
  • [45] Involved-field (IF) Versus Extended-field (EF) Radiation Therapy (RT) for Patients in Early Unfavorable Stages of Hodgkin Lymphoma: 10-year Update of the HD8 Trial of the German Hodgkin Study Group (GHSG)
    Eich, H. T.
    Kriz, J.
    Klimm, B.
    Sasse, S.
    Goergen, H.
    Diehl, V.
    Borchmann, P.
    Mueller, R.
    Engert, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S70 - S70
  • [46] Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial
    Baues, Christian
    Goergen, Helen
    Fuchs, Michael
    Rosenbrock, Johannes
    Celik, Eren
    Eich, Hans
    Kobe, Carsten
    Voltin, Conrad-Amadeus
    Engert, Andreas
    Borchmann, Peter
    Marnitz, Simone
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (04): : 900 - 906
  • [47] Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial
    Thomas, Jose
    Ferme, Christophe
    Noordijk, Evert M.
    Morschhauser, Franck
    Girinsky, Theodore
    Gaillard, Isabelle
    Lugtenburg, Pieternella J.
    Andre, Marc
    Lybeert, Marnix L. M.
    Stamatoullas, Aspasia
    Beijert, Max
    Helias, Philippe
    Eghbali, Houchingue
    Gabarre, Jean
    van der Maazen, Richard W. M.
    Jaubert, Jerome
    Bouabdallah, Krimo
    Boulat, Olivier
    Roesink, Judith M.
    Christian, Bernard
    Ong, Francisca
    Bordessoule, Dominique
    Tertian, Gerard
    Gonzalez, Hugo
    Vranovsky, Andrej
    Quittet, Philippe
    Tirelli, Umberto
    de Jong, Daphne
    Audouin, Josee
    Aleman, Berthe M. P.
    Henry-Amar, Michel
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1133 - 1145
  • [48] Results of the EORTC-GELA H9 randomized trials:: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL)
    Thomas, J.
    Ferme, C.
    Noordijk, E. M.
    van't Veer, M. B.
    Brice, P.
    Divine, M.
    Morschhauser, F.
    Carde, P.
    Eghbali, H.
    Henry-Amar, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 27 - 27
  • [49] First results of the EORTC-GELA H9 randomized trials:: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL).
    Noordijk, EM
    Thomas, J
    Fermé, C
    Van 't Veer, MB
    Brice, P
    Diviné, M
    Morschhauser, F
    Carde, P
    Eghbali, H
    Henry-Amar, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 561S - 561S
  • [50] Positronenemissionstomographie(PET)-geleitete Behandlung des Hodgkin-Lymphoms im frühen Stadium mit günstigen Risikofaktoren: Endresultate der internationalen randomisierten Phase-III-HD16-Studie der Deutschen Hodgkin-StudiengruppePositron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international randomized phase III HD16 trial conducted by the German Hodgkin Study Group
    Carsten Nieder
    Strahlentherapie und Onkologie, 2020, 196 (4) : 414 - 415
12345